Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multice...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Ferrata Storti Foundation
2021-07-01
|
| Серія: | Haematologica |
| Онлайн доступ: | https://haematologica.org/article/view/10347 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|